---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059107"
form_type: "8-K"
ticker: null
cik: "0001697532"
company_name: "Applied Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:26:24.824869+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Applied Therapeutics Q1 net loss $83.9M; govorestat NDA PDUFA Nov 28, 2024

## Summary
- Net loss $83.9M ($0.67/share) vs $10.1M ($0.18/share) Q1 2023; cash $146.5M up from $49.9M.
- Govorestat NDA for Classic Galactosemia under priority review; PDUFA date Nov 28, 2024.
- MAA under EMA review; decision expected early Q1 2025 after Day 120 clock-stop extension.
- Discussing potential NDA submission for SORD Deficiency under Accelerated Approval with FDA.
- Appointed Dale Hooks as Chief Commercial Officer; presented Phase 3 ARISE-HF data at ACC.

## SEC filing metadata
- accession: 0001104659-24-059107
- form_type: 8-K
- cik: 0001697532
- company_name: Applied Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1697532/000110465924059107/0001104659-24-059107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1697532/000110465924059107/tm2413888d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059107
- JSON: https://secwatch.observer/filing/0001104659-24-059107.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059107.txt

## Key facts
- Earnings Releases
  Applied Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $146.5 million, net income $83.9 million, EPS $0.67 per basic and diluted common share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $146.5 million
  - Net income: $83.9 million
  - EPS: $0.67 per basic and diluted common share
  - Result: reported results
  source text: full study results were published in the Journal of the American College of Cardiology (JACC). Financial Results · Cash and cash equivalents and short-term investments totaled $146.5 million as of March 31, 2024, compared with $49.9 million at December 31, 2023. · Research and development expenses for the three months ended March 31, 2024, were $12.2 million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1697532/000110465924059107/0001104659-24-059107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.